$OCUL
OCULAR THERAPEUTIX, INC

2022 Q3 Form 10-Q Financial Statement

#000155837022012623 Filed on August 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $11.97M $12.27M $13.19M
YoY Change -1.55% 4.68% 79.61%
Cost Of Revenue $1.073M $1.155M $1.300M
YoY Change -18.09% 5.38% 45.74%
Gross Profit $10.89M $11.11M $11.89M
YoY Change 0.45% 4.6% 84.29%
Gross Profit Margin 91.03% 90.58% 90.14%
Selling, General & Admin $18.72M $17.93M $16.62M
YoY Change 6.03% 5.49% 5.52%
% of Gross Profit 171.84% 161.34% 139.82%
Research & Development $13.72M $13.10M $13.10M
YoY Change 7.86% -5.48% 19.89%
% of Gross Profit 125.95% 117.9% 110.2%
Depreciation & Amortization $509.0K $552.0K $557.0K
YoY Change -14.31% -9.06% -13.78%
% of Gross Profit 4.67% 4.97% 4.69%
Operating Expenses $32.44M $31.03M $29.72M
YoY Change 6.8% 0.56% 11.4%
Operating Profit -$21.54M -$19.92M -$17.83M
YoY Change 10.32% -1.56% -11.84%
Interest Expense $1.797M $1.696M $1.683M
YoY Change 8.38% 2.48% 0.24%
% of Operating Profit
Other Income/Expense, Net -$2.644M $1.150M $5.291M
YoY Change -111.92% -90.21% -77.34%
Pretax Income -$24.19M -$18.77M -$12.54M
YoY Change -1010.35% 121.27% -501.99%
Income Tax
% Of Pretax Income
Net Earnings -$24.19M -$18.77M -$12.54M
YoY Change -1010.35% 121.27% -501.86%
Net Earnings / Revenue -202.16% -152.99% -95.11%
Basic Earnings Per Share -$0.31 -$0.24 -$0.16
Diluted Earnings Per Share -$0.31 -$0.25 -$0.22
COMMON SHARES
Basic Shares Outstanding 76.97M 76.76M 76.75M
Diluted Shares Outstanding 76.98M 82.53M 82.51M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $121.0M $134.5M $145.4M
YoY Change -32.54% -29.88% -30.56%
Cash & Equivalents $121.0M $134.5M $145.4M
Short-Term Investments
Other Short-Term Assets $3.318M $3.801M $4.670M
YoY Change -14.42% -21.09% 16.75%
Inventory $1.545M $1.500M $1.358M
Prepaid Expenses
Receivables $19.80M $20.48M $23.21M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $145.6M $160.3M $174.7M
YoY Change -28.6% -25.96% -23.44%
LONG-TERM ASSETS
Property, Plant & Equipment $7.196M $6.680M $6.614M
YoY Change 4.08% -5.14% -12.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.764M $1.764M $1.764M
YoY Change 0.0% 0.0% -2.0%
Total Long-Term Assets $12.96M $12.75M $12.97M
YoY Change -6.11% -10.12% -13.0%
TOTAL ASSETS
Total Short-Term Assets $145.6M $160.3M $174.7M
Total Long-Term Assets $12.96M $12.75M $12.97M
Total Assets $158.6M $173.1M $187.6M
YoY Change -27.17% -24.98% -22.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.308M $3.703M $3.420M
YoY Change 25.01% -4.59% -17.63%
Accrued Expenses $21.61M $19.45M $17.64M
YoY Change 11.65% 20.2% 29.92%
Deferred Revenue $603.0K $1.189M $1.208M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $29.27M $26.11M $23.96M
YoY Change 16.34% 21.17% -12.67%
LONG-TERM LIABILITIES
Long-Term Debt $53.34M $52.70M $52.06M
YoY Change 4.96% 4.89% 31.13%
Other Long-Term Liabilities $29.74M $28.46M $31.81M
YoY Change -45.36% -63.82% -65.61%
Total Long-Term Liabilities $83.08M $81.16M $83.87M
YoY Change -21.06% -37.05% -36.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $29.27M $26.11M $23.96M
Total Long-Term Liabilities $83.08M $81.16M $83.87M
Total Liabilities $112.4M $107.3M $107.8M
YoY Change -13.84% -28.71% -32.45%
SHAREHOLDERS EQUITY
Retained Earnings -$601.3M -$577.1M -$558.3M
YoY Change 10.95% 5.97% 4.14%
Common Stock $647.5M $642.9M $638.1M
YoY Change 2.9% 2.89% 3.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $46.23M $65.80M $79.80M
YoY Change
Total Liabilities & Shareholders Equity $158.6M $173.1M $187.6M
YoY Change -27.17% -24.98% -22.8%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$24.19M -$18.77M -$12.54M
YoY Change -1010.35% 121.27% -501.86%
Depreciation, Depletion And Amortization $509.0K $552.0K $557.0K
YoY Change -14.31% -9.06% -13.78%
Cash From Operating Activities -$13.17M -$10.88M -$18.60M
YoY Change 1.44% -45.77% 7.15%
INVESTING ACTIVITIES
Capital Expenditures -$794.0K -$495.0K $276.0K
YoY Change 187.68% 289.76% 74.68%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$794.0K -$495.0K -$276.0K
YoY Change 187.68% 289.76% 74.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 374.0K 493.0K 129.0K
YoY Change -44.92% -81.5% -111.1%
NET CHANGE
Cash From Operating Activities -13.17M -10.88M -18.60M
Cash From Investing Activities -794.0K -495.0K -276.0K
Cash From Financing Activities 374.0K 493.0K 129.0K
Net Change In Cash -13.59M -10.88M -18.75M
YoY Change 8.03% -37.9% 0.36%
FREE CASH FLOW
Cash From Operating Activities -$13.17M -$10.88M -$18.60M
Capital Expenditures -$794.0K -$495.0K $276.0K
Free Cash Flow -$12.38M -$10.38M -$18.88M
YoY Change -2.61% -47.91% 7.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6680000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4751000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6956000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11718000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25453000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19061000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1988000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
160322000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
191300000
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q2 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021Q2 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76731940
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76910026
dei Entity Central Index Key
EntityCentralIndexKey
0001393434
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36554
dei Entity Registrant Name
EntityRegistrantName
Ocular Therapeutix, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-5560161
dei Entity Address Address Line1
EntityAddressAddressLine1
24 Crosby Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Bedford
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01730
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
357-4000
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
OCUL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
76966889
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
134539000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
164164000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
20482000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21135000
CY2022Q2 us-gaap Inventory Net
InventoryNet
1500000
CY2021Q4 us-gaap Inventory Net
InventoryNet
1250000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3801000
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1155000
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1096000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2454000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1624000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
26113000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26337000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4305000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4867000
CY2022Q2 us-gaap Assets
Assets
173071000
CY2021Q4 us-gaap Assets
Assets
204887000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3703000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4592000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19450000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20121000
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1189000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1771000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4999000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5924000
CY2022Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
10461000
CY2021Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
20192000
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
13000000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
13000000
CY2022Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
25128000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
25000000
CY2022Q2 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
27567000
CY2021Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
26435000
CY2022Q2 us-gaap Liabilities
Liabilities
107268000
CY2021Q4 us-gaap Liabilities
Liabilities
116888000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
76910026
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
76731940
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
8000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
642907000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
633795000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-577112000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-545804000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
65803000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
87999000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
173071000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
204887000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12266000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13100000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13859000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26200000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24786000
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10140000
CY2021Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8391000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
19203000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
16477000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7787000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8603000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15344000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16268000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
32182000
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
31949000
us-gaap Costs And Expenses
CostsAndExpenses
63201000
us-gaap Costs And Expenses
CostsAndExpenses
59519000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-19916000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20231000
us-gaap Operating Income Loss
OperatingIncomeLoss
-37748000
us-gaap Operating Income Loss
OperatingIncomeLoss
-40458000
CY2022Q2 us-gaap Investment Income Net
InvestmentIncomeNet
73000
CY2021Q2 us-gaap Investment Income Net
InvestmentIncomeNet
8000
us-gaap Investment Income Net
InvestmentIncomeNet
89000
us-gaap Investment Income Net
InvestmentIncomeNet
20000
CY2022Q2 us-gaap Interest Expense
InterestExpense
1696000
CY2021Q2 us-gaap Interest Expense
InterestExpense
1655000
us-gaap Interest Expense
InterestExpense
3378000
us-gaap Interest Expense
InterestExpense
3335000
CY2022Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2773000
CY2021Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
13396000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
9731000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
38412000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1150000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11750000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6440000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
35098000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-18766000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-8481000
us-gaap Net Income Loss
NetIncomeLoss
-31308000
us-gaap Net Income Loss
NetIncomeLoss
-5360000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76764296
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76324367
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-29625000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76755028
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76198384
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82533528
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82093599
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82524260
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81967616
us-gaap Profit Loss
ProfitLoss
-31308000
us-gaap Profit Loss
ProfitLoss
-5360000
us-gaap Share Based Compensation
ShareBasedCompensation
8490000
us-gaap Share Based Compensation
ShareBasedCompensation
7378000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2391000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2282000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
9731000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
38412000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1109000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1257000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-653000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6482000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-950000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
167000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
250000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-89000
ocul Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-562000
ocul Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-466000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-809000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1255000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1946000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
928000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1189000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-778000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-649000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29476000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37415000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
771000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
287000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-771000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-287000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
3722000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
140000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1735000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
482000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
490000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
275000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4167000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
622000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1505000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4209000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-12542000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
79795000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
482000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
87999000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
129000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-36197000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165928000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229821000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
136303000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
193624000
us-gaap Interest Paid Net
InterestPaidNet
990000
us-gaap Interest Paid Net
InterestPaidNet
1065000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
245000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
8000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4281000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-18766000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
65803000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
76095000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1197000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
91000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3086000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
3121000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
83408000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
538000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
490000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4292000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-8481000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
80247000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-577112000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
134539000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><span style="margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.13;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.13;text-align:justify;margin:0pt;">limited to, revenue recognition, clinical trial accruals and the fair value of derivatives.  Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results may differ from these estimates.  </p>
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76198384
CY2021Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
5769232
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk and of Significant Suppliers and Customers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><span style="font-style:italic;font-weight:bold;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">The Company is dependent on a small number of third-party manufacturers to supply products for research and development activities in its preclinical and clinical programs and for sales of its products. The Company’s development programs as well as revenue from future product sales could be adversely affected by a significant interruption in the supply of any of the components of these products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">For the three and six months ended June 30, 2022, four specialty distributor customers accounted for 41%, 26%, 17%, and 10%, and three specialty distributor customers accounted for 41%, 25% and 20%<span style="white-space:pre-wrap;">, respectively, of the Company’s total product revenue, and no other customer accounted for more than 10% of the Company’s total product revenue. At June 30, 2022, </span>four specialty distributor customers accounted for 46%, 25%, 16% and 10% of the Company’s total accounts receivable and no other customer accounted for more than 10% of the Company’s total accounts receivable at June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">For the three and six months ended June 30, 2021, three specialty distributor customers accounted for 45%, 28%<span style="white-space:pre-wrap;">, and </span>15%, and 45%, 25% and 14%<span style="white-space:pre-wrap;">, respectively, of the Company’s total product revenue, and no other customer accounted for more than 10% of the Company’s total product revenue. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">At December 31, 2021, three specialty distributor customers accounted for 42%, 26% and 21% of the Company’s total accounts receivable. No other customer accounted for more than 10% of total accounts receivable for the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p>
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
134539000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
191860000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
136303000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
193624000
CY2022Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
5769232
CY2022Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
325000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
388000
CY2022Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
662000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
605000
CY2022Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
513000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
257000
CY2022Q2 us-gaap Inventory Net
InventoryNet
1500000
CY2021Q4 us-gaap Inventory Net
InventoryNet
1250000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4747000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6597000
CY2022Q2 ocul Accrued Rebates And Programs Current
AccruedRebatesAndProgramsCurrent
3260000
CY2021Q4 ocul Accrued Rebates And Programs Current
AccruedRebatesAndProgramsCurrent
3615000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1081000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1227000
CY2022Q2 ocul Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1683000
CY2021Q4 ocul Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1102000
CY2022Q2 ocul Debt Instrument Accrued Interest
DebtInstrumentAccruedInterest
7606000
CY2021Q4 ocul Debt Instrument Accrued Interest
DebtInstrumentAccruedInterest
6475000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1073000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1105000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19450000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20121000
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
20192000
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
9731000
CY2022Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
10461000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
13000000
ocul Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
2000000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
811000
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
14189000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81967616
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-18766000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-8481000
us-gaap Net Income Loss
NetIncomeLoss
-31308000
us-gaap Net Income Loss
NetIncomeLoss
-5360000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76764296
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76324367
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76755028
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76198384
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18766000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8481000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-31308000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5360000
CY2022Q2 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
1141000
CY2021Q2 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
1095000
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
2264000
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
2173000
CY2022Q2 us-gaap Dilutive Securities
DilutiveSecurities
-2773000
CY2021Q2 us-gaap Dilutive Securities
DilutiveSecurities
-13396000
us-gaap Dilutive Securities
DilutiveSecurities
-9731000
us-gaap Dilutive Securities
DilutiveSecurities
-38412000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-20398000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-20782000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-38775000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-41599000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76764296
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76324367
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76755028
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
5769232
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
5769232
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82533528
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82093599
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82524260
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14909995
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11049287
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4281000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4292000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8490000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7378000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
25612000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D

Files In Submission

Name View Source Status
0001558370-22-012623-index-headers.html Edgar Link pending
0001558370-22-012623-index.html Edgar Link pending
0001558370-22-012623.txt Edgar Link pending
0001558370-22-012623-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ocul-20220630.xsd Edgar Link pending
ocul-20220630x10q.htm Edgar Link pending
ocul-20220630xex10d1.htm Edgar Link pending
ocul-20220630xex10d2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ocul-20220630x10q_htm.xml Edgar Link completed
ocul-20220630xex10d2001.jpg Edgar Link pending
ocul-20220630xex10d2002.jpg Edgar Link pending
ocul-20220630xex31d1.htm Edgar Link pending
ocul-20220630xex31d2.htm Edgar Link pending
ocul-20220630xex32d1.htm Edgar Link pending
ocul-20220630xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
ocul-20220630_def.xml Edgar Link unprocessable
ocul-20220630_pre.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ocul-20220630_lab.xml Edgar Link unprocessable
ocul-20220630_cal.xml Edgar Link unprocessable